06160
JPMorgan Chase & Co's Short Position in Shares of Beigene Decreases to 1.66% on Dec. 11 From 2.42% - HKEX
时间：2024-12-16 17:29:49 市场： 综合
Beigene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of Pd-1 Inhibitors, Including Tevimbra®, for Treatment of Escc and Gastric/Gej Cancers
时间：2024-09-27 06:21:00 市场： 综合
Global Oncology Innovator Beigene Appoints Shalini Sharp to Board of Directors
时间：2024-09-26 18:00:01 市场： 综合
Beigene Receives Israeli Ministry of Health Approval for Tevimbra® for the Treatment of Oesophageal Squamous Cell Carcinoma (Oscc) After Prior Chemotherapy
时间：2024-09-17 19:03:42 市场： 综合